Early-Phase RAS Inhibitor Research Sparks Interest in NSCLC: With Kathryn C. Arbour, MD
9 mins; May 08, 2025
Managing Side Effects and Fertility for Premenopausal Patients with Advanced HR+ Breast Cancer
64 hours 27 mins; May 07, 2025
RP1 Plus Nivolumab Delivers Durable Responses in PD-1–Exposed Melanoma: With Anna C. Pavlick, BSN, MSc, DO, MBA
10 mins; May 05, 2025
Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH
12 mins; May 01, 2025
Disease Features and Treatment Intolerance Inform Pirtobrutinib Use in Pretreated CLL: With Nicole Lamanna, MD
19 mins; April 28, 2025
Radioligand Therapy Advances Represent the Future of mCRPC Treatment: With Daniel P. Petrylak, MD
7 mins; April 24, 2025
Oncodetect MRD Detection Aids Treatment Decision-Making in CRC and Other Solid Tumors: With Eric Christenson, MD
13 mins; April 23, 2025
Motivation and Consistency Are Key to Building a Successful Oncology Educational Platform: With Chandler Park, MD; and Paul Hanona, MD
9 mins; April 21, 2025
Social Media Unlocks New Avenues for Expanding Access to Oncology Education: With Chandler Park, MD; and Paul Hanona, MD
12 mins; April 16, 2025
Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC
44 mins; April 16, 2025
Bladder-Sparing Strategies and ctDNA-Guided Strategies Take Center Stage in MIBC: With Chandler Park, MD; and Vadim Koshkin, MD
5 mins; April 14, 2025
Peer Support, Adaptability, and Self-Confidence Are Hallmarks of Successful Oncology Careers: With Liliana Bustamante, MD; and Jessica Stine, MD
23 mins; April 10, 2025
Innovative Research Raises Questions About the Role of ADCs in Bladder Cancer: With Chandler Park, MD; and Vadim Koshkin, MD
13 mins; April 09, 2025
AR Pathway Inhibition Refines Prostate Cancer Treatment Strategies: With Neal Shore, MD, FACS
8 mins; April 07, 2025
Comprehensive First-Line Bladder Cancer Treatment Begins With Careful Patient Selection: With Chandler Park, MD
18 mins; April 03, 2025
ADC-Based Combinations Gain Momentum in Bladder Cancer Management: With Chandler Park, MD; and Vadim Koshkin, MD
10 mins; April 02, 2025
Oncology Experts Discuss the Long-Term Effects of the COVID-19 Pandemic: With Ramez N. Eskander, MD; Rachel N. Grisham, MD; Benjamin Herzberg, MD; Kelly McCann, MD, PhD; and Gregory Roloff, MD
13 mins; March 31, 2025
Study Reveals Subgroups of Patients With RCC Who May Have Durable Responses to Immunotherapy: With David A. Braun, MD, PhD
15 mins; March 27, 2025
Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc
20 mins; March 26, 2025
Ivonescimab Improves PFS vs Pembrolizumab in Advanced PD-L1+ NSCLC: With Xiuning Le, MD, PhD
11 mins; March 24, 2025
Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD
9 mins; March 20, 2025
Venetoclax Plus Pegcrisantaspase Induces Remissions in R/R AML: With Ashkan Emadi, MD, PhD
19 mins; March 17, 2025
FDA Approval Insights: Tislelizumab Plus Chemo in Unresectable Metastatic ESCC: With Nataliya Uboha, MD, PhD
9 mins; March 13, 2025
Perioperative Durvalumab Improves Survival in MIBC: Navigating the NIAGARA Trial Findings With: Chandler Park, MD; and Petros Grivas, MD, PhD
23 mins; March 12, 2025
Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes
54 mins; March 11, 2025
Inavolisib Expands the PIK3CA-Mutated Metastatic HR+ Breast Cancer Treatment Paradigm: With Virginia Kaklamani, MD, DSc
5 mins; March 10, 2025
FDA Approval Insights: Vimseltinib for Symptomatic TGCT: With William D. Tap, MD
7 mins; March 06, 2025
Clinical Showcaseâ„¢: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma
30 mins; March 04, 2025
FDA Approval Insights: Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC: With Marwan Fakih, MD
7 mins; March 03, 2025
FDA Approval Insights: T-DXd in HER2-Low/-Ultralow Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO
7 mins; February 27, 2025
Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD
20 mins; February 26, 2025
Triplet Chemo Trial Raises Importance of Accurately Defined Subgroups in Biliary Tract Cancer Research: With Rachna Shroff, MD, MS, FASCO
11 mins; February 24, 2025
DA Approval Insights: Mirdametinib for NF1-Associated Plexiform Neurofibromas: With Christopher L. Moertel, MD
11 mins; February 20, 2025
Inavolisib Has a Favorable Risk-Benefit Profile for PIK3CA-Mutant, HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP
14 mins; February 17, 2025
FDA Approval Insights: Dato-DXd for HR+/HER2-Negative Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO
6 mins; February 13, 2025
Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD
30 mins; February 10, 2025
Advances in RAS-Mutant PDAC Management Emphasize the Importance of Biomarker Testing: With Heinz-Josef Lenz, MD
9 mins; February 06, 2025
How Academia and Industry Intersect to Improve Oncology Research and Patient Care: With D. Ross Camidge, MD, PhD; and Tim Eisen, MB BChir, PhD
62 hours 5 mins; February 05, 2025
Olverembatinib Research Signals a New Era of CP-CML Management: With Elias Jabbour, MD
5 mins; February 03, 2025
How Second Primary Cancer Risk Factors Into CAR T-Cell Therapy Considerations: With Saurabh Dahiya, MD, FACP; and Shyam A. Patel, MD, PhD
21 mins; January 30, 2025
How are Antibody-Drug Conjugates Shaping the NSCLC Treatment Paradigm? With David Gerber, MD
27 mins; January 27, 2025
Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD
19 mins; January 23, 2025
FDA Approval Insights: Subcutaneous Nivolumab for Advanced Solid Tumors: With Roxana S. Dronca, MD
10 mins; January 20, 2025
MedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MD
19 mins; January 15, 2025
Oncogene Analysis Identifies Clinically Relevant Gene Copy Number Gain Thresholds in NSCLC: With Alec Watson, MD
30 mins; January 13, 2025
Clinical Practice Insights Reveal the Complexity of Lymphoma Subtypes and Advances in First-Line Treatments: With Chandler Park, MD; and Joshua Brody, MD
23 mins; January 08, 2025
Pembrolizumab Plus Preoperative Radiotherapy and Surgery Improves DFS in Soft-Tissue Sarcoma: With Yvonne Mowery, MD, PhD
16 mins; January 06, 2025
FDA Approval Insights: Zenocutuzumab for NRG1+ Pancreatic Adenocarcinoma and NSCLC: With Alison Schram, MD
5 mins; January 02, 2025
DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD
18 mins; January 01, 2025
Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD
23 mins; December 31, 2024
FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer
14 mins; December 30, 2024
Exploring Luspatercept's Role in Anemia Management for Lower-Risk MDS: Insights From Dr. Jorge Cortes
8 mins; December 24, 2024
The Evolving Role of ctDNA in Guiding Adjuvant Chemotherapy Decisions in CRC: Insights from Stacey A. Cohen, MD
17 mins; December 24, 2024
Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD
13 mins; December 23, 2024
Explore MRD Dynamics With Isa-VRd in Newly Diagnosed Multiple Myeloma: Insights From Philippe Moreau, MD
8 mins; December 23, 2024
Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH
14 mins; December 19, 2024
Unpacking Key Data From the 2024 ASH Annual Meeting: With Andre Goy, MD
23 mins; December 17, 2024
Exploring Lasofoxifene Plus Abemaciclib in ESR1+ Breast Cancer: Insights from ELAINE-3 With Sagar D. Sardesai, MBBS
4 mins; December 16, 2024
Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD
15 mins; December 12, 2024
Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD
16 mins; December 11, 2024
T-DXd Steadily Transforms the NSCLC Treatment Paradigm: With Misako Nagasaka, MD, PhD
10 mins; December 09, 2024
How to Optimize Patient Selection for Multiple Myeloma Therapies: With Binod Dhakal, MD; and Muhamed Baljevic, MD
36 mins; December 05, 2024
Pancreatic Cancer Research Surfaces Treatment Developments and Challenges: With John Strickler, MD
13 mins; December 02, 2024
FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL
8 mins; November 28, 2024
Explore the Latest Treatment Updates in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen V. Liu, MD
11 mins; November 27, 2024
Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD
12 mins; November 25, 2024
Trastuzumab Deruxtecan Advances HER2+ Gynecologic Cancer Care: With Susana M. Campos, MD, MPH
7 mins; November 21, 2024
HPV16-Targeted Immunotherapy Is Set to Personalize HNSCC Management: With Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB
16 mins; November 18, 2024
FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma
10 mins; November 14, 2024
Relacorilant Plus Nab-Paclitaxel Carves New Avenues of Platinum-Resistant Ovarian Cancer Care: With Premal Thaker, MD, MS
9 mins; November 11, 2024
Explore Emerging Breast Cancer Treatment Trends With Kevin Kalinsky, MD, MS
11 mins; November 07, 2024
Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD
11 mins; November 06, 2024
How to Use Toripalimab Plus Chemotherapy in Nasophryngeal Carcinoma: With Tarek Mekhail, MD, MSC, FRCSI, FRCSEd
9 mins; November 04, 2024
SUNLIGHT QOL Data Show Positive Outcomes With T rifluridine-Tipiracil Plus Bevacizumab in CRC : With Joleen Hubbard, MD
10 mins; October 31, 2024
Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
20 mins; October 30, 2024
Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing: With David R. Gandara, MD
11 mins; October 28, 2024
Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
11 mins; October 24, 2024
Phase 1 Trials Provide Oncology Fellows With Valuable Clinical Research Experience: With Samuel A. Kareff, MD, MPH
14 mins; October 21, 2024
FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL
8 mins; October 17, 2024
How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
17 mins; October 16, 2024
Navigating Myelofibrosis: Updates for Community Hematologist Oncologists
25 mins; October 14, 2024
FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma
12 mins; October 10, 2024
Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD
11 mins; October 07, 2024
FDA Approval Insights: Perioperative Durvalumab for Resectable NSCLC
15 mins; October 03, 2024
Immunotherapy Advances Expand the SCLC Treatment Paradigm: With Chandler Park, MD, and Tejas Patil, MD
15 mins; October 02, 2024
Board Review Resources 2024
15 mins; September 30, 2024
How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD
13 mins; September 26, 2024
FDA Approval Insights: Afami-Cel for Pretreated, Unresectable or Metastatic Synovial Sarcoma
13 mins; September 23, 2024
Thomas and Lukas Highlight Updates in Brain Cancer from the 2024 ASCO Annual Meeting
15 mins; September 19, 2024
Park and Patil Explore Advances in EGFR + NSCLC From ASCO 2024
19 mins; September 18, 2024
FDA Approval Insights: Epcoritamab in Relapsed/Refractory Follicular Lymphoma
9 mins; September 16, 2024
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
11 mins; September 11, 2024
Heme & Onc Fellow Board Review Tips 2024
16 mins; September 09, 2024
Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions
11 mins; September 05, 2024
Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer
21 mins; September 04, 2024
Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC
12 mins; September 02, 2024
Chiang Contextualizes the Optimal Use of Lurbinectedin in SCLC Management
8 mins; August 29, 2024
FDA Approval Insights: Dostarlimab Plus Chemotherapy in Advanced/Recurrent Endometrial Cancer
8 mins; August 26, 2024
Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer
9 mins; August 22, 2024
Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC
